ArticleCureus2023
In Vitro Anti-diabetic Activity of Pomegranate Peel Extract-Mediated Strontium Nanoparticles.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Enzyme Inhibition by Bioactive Compounds from Olive (Molecules (Basel, Switzerland) · 2026Pooled it
- Peel of Pomegranate Fruit (Current issues in molecular biology · 2026Article
- Phytochemical Profile and α-Amylase Inhibitory Activity of Pomegranate Peel Extract: An In Silico and In Vitro Investigation.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Type 2 diabetes mellitus and its associated health complications represent a significant public health issue due to its wide prevalence. The primary disadvantages of current oral anti-diabetic drugs are their limited bio-availability and their quick release, which necessitates more frequent dosing. Similar limitations are encountered when using natural products for the management of type 2 diabetes. Consequently, nanoparticles have been developed with the goal of enhancing the physicochemical stability of the drugs, thereby improving their bio-availability. In view of the given background, the present study aimed to explore the efficacy of strontium nanoparticles derived from pomegranate peel extract in managing type 2 diabetes mellitus. Materials and methods The aqueous extract of pomegranate peel was prepared using standard protocol and the strontium nanoparticles were prepared by green synthesis method using pomegranate peel extract. The prepared aqueous extract of pomegranate peel and the nanoparticles were assessed for their inhibitory potential against α-amylase and α-glucosidase enzymes activity by 3,5-dinitrosalicylic acid (DNSA) and p-nitro-phenyl-ɑ-D glucopyranoside (p-NPG) assays, respectively. Results The pomegranate peel-mediated strontium nanoparticles (PP-Sr NPs) and standard acarbose were assessed for their inhibitory effect against diabetic enzymes, α-amylase, and α-glucosidase at different concentrations range of 5-160 μg/ml. The results showed that PP-Sr NPs exhibited a maximum inhibition of 79.28% and 76.17% against α-amylase and α-glucosidase respectively at the highest concentration of 160 μg/ml. Acarbose showed a maximum inhibition of 88.02% and 84.47% against α-amylase and α-glucosidase respectively at 160 μg/ml. The inhibitory effect of the PP-Sr NPs and standard acarbose was found to be concentration-dependent. Conclusion From the results, it is concluded that the PP-Sr NPs may be useful for decreasing postprandial glucose levels. Further studies using in vitro cell lines and in vivo diabetic models may substantiate the antidiabetic potential of PP-Sr NPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.